Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Screening Protocol to Assess the Expression of Tumor Associated Antigens (TAAs), Human Papillomavirus (HPV-16) Antigens and Human Leucocyte Antigen (HLA) Sub-Types in Patients With Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers.

NCT05061940 is registered in ClinicalTrials.gov with Repertoire Immune Medicines as lead sponsor.

NCT NCT05061940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05061940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Screening Protocol to Assess the Expression of Tumor Associated Antigens (TAAs), Human Papillomavirus (HPV-16) Antigens and Human Leucocyte Antigen (HLA) Sub-Types in Patients With Head and Neck, Cervical, Melanoma and Non-Small Cell Lung Cancers.
Lead sponsor
Repertoire Immune Medicines
Phase
Observational
Overall status
Terminated
Start date
May 5, 2021
Completion date
October 11, 2022
Enrollment
22 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, hpv positive oropharyngeal squamous cell carcinoma, hpv-related carcinoma, hpv-related cervical carcinoma, hpv-related malignancy, lung cancer, nonsmall cell, melanoma, melanoma (skin)